Abstract: Objective To explore the changes in optical coherence tomography angiography(OCTA) of eyes with wet age-related macular degeneration(wAMD) before and after intravitreal injection of anti-vascular endothelial growth factor(VEGF) drugs and its correlation with visual acuity. 
Methods The data of 72 wAMD patients(72 eyes) who received intravitreal injection of anti-VEGF drugs were retrospectively analyzed, and the changes of cross sectional area(CSA), cross flow area(CFA), and central macular thickness(CMT) before and after treatment were compared. The standard logarithmic visual acuity chart was used to check the patient's best corrected visual acuity(BCVA) before and after treatment, which was converted into LogMAR visual acuity chart values. Pearson correlation analysis was used to analyze the relationship between difference of CSA, CFA, CMT and difference of BCVA(LogMAR) before and after treatment with anti-VEGF drugs in wAMD eyes, and the therapeutic effect of patients was calculated. Logistic regression analysis was used to analyze the factors influencing the ineffectiveness of anti-VEGF drug treatment in wAMD eyes. 
Results CSA, CFA and CMT after anti-VEGF drugs in wAMD eyes were lower than those before treatment(P＜0.05). BCVA(LogMAR) after anti-VEGF drug treatment in wAMD eyes was lower than that before treatment(P＜0.05). According to Pearson correlation analysis, difference of CSA, CFA, CMT before and after anti-VEGF drug treatment in wAMD eyes were positively correlated with difference of BCVA(LogMAR)(P＜0.05). Logistic multivariate regression analysis showed that preoperative intraocular pressure, pretreatment CSA, CFA, and CMT were related factors that affected the ineffectiveness of anti-VEGF drug treatment in wAMD eyes(P＜0.05). 
Conclusion Difference of CSA, CFA, CMT before and after treatment with anti-VEGF drugs in wAMD eyes are positively correlated with difference of BCVA(LogMAR) before and after treatment, and CSA, CFA, and CMT are all related factors that affect the therapeutic effect of anti-VEGF drugs in wAMD eyes.

Key words: